Ornithine transcarbamylase (OTC) deficiency is the most common inherited disorder of the urea cycle, the metabolic pathway your liver uses to convert toxic ammonia into urea so you can safely excrete it. When the OTC enzyme is missing or not working well enough, ammonia builds up in the blood and can damage the brain, sometimes fatally. Because the gene responsible sits on the X chromosome, the condition follows an X-linked inheritance pattern that hits boys hardest but can also cause serious illness in girls and women. The range of severity is enormous, stretching from catastrophic illness in the first days of life to subtle episodes that go unrecognized for decades.
What the OTC Enzyme Does and Why It Matters
The urea cycle is a chain of chemical reactions, mostly housed in the liver, that detoxifies ammonia produced when your body breaks down protein. OTC is a mitochondrial enzyme that catalyzes one critical step: joining ornithine and carbamoyl phosphate to form citrulline.1PubMed. Ornithine transcarbamylase deficiency: a urea cycle defect When this step stalls, ammonia that should be on its way to becoming harmless urea instead accumulates in the bloodstream. Even moderately elevated ammonia is neurotoxic. During a metabolic crisis, rising blood ammonia drives up glutamine levels in the brain, worsening cerebral swelling and neurological symptoms.2PubMed Central. Neurotoxic Effects of Ammonia in a Patient With Ornithine Transcarbamylase Deficiency and Bilateral Brain Abscesses
How OTC Deficiency Is Inherited
The OTC gene is on the X chromosome. Males have only one X, so a single defective copy leaves them with little or no working enzyme. That is why the most severe, neonatal-onset form overwhelmingly affects boys: within the first few days of life, ammonia surges to dangerous levels. Females carry two X chromosomes, and because of a process called X-inactivation, each liver cell randomly silences one copy. The proportion of cells that happen to silence the normal copy versus the mutated one determines how much functional enzyme a woman ends up with. Some female carriers have enough working enzyme to remain symptom-free their entire lives; others develop disease nearly as severe as affected males.3American Academy of Pediatrics (Pediatrics). An Integrated Approach to the Diagnosis and Prospective Management of Partial Ornithine Transcarbamylase Deficiency
There is also a less intuitive route to the disease. In one documented case, an 18-month-old boy was found to carry a mosaic frameshift mutation in the OTC gene. “Mosaic” means the mutation arose after conception, so only some of his cells carried it while others had a normal copy. Because enough normal cells were producing enzyme, his disease was milder than expected for a mutation that would otherwise knock out OTC completely.4PubMed Central. Late-onset ornithine transcarbamylase deficiency caused by a somatic mosaic mutation Cases like this are a reminder that genetic testing results need careful interpretation: the same mutation can produce very different outcomes depending on when and where it occurred.
Neonatal Onset Versus Late Onset
The classic textbook picture is the newborn boy who feeds normally for a day or two, then rapidly becomes lethargic, stops feeding, and develops seizures as ammonia skyrockets. Without aggressive treatment, this scenario can be fatal within days. But this dramatic presentation is only one end of the spectrum.
Late-onset OTC deficiency is far sneakier. People with partial enzyme activity can go years, sometimes decades, without a recognized episode. Their remaining enzyme handles everyday protein loads just well enough, but a metabolic stressor pushes them over the edge. That stressor could be a high-protein meal, an infection, surgery, certain medications, or even prolonged fasting. One case report describes a man whose episodes of confusion were traced to a recent increase in daily protein intake.5PubMed Central. Late-onset ornithine transcarbamylase deficiency: a rare cause of recurrent abnormal behavior in adults His symptoms had been chalked up to other causes until blood work finally revealed sky-high ammonia.
Late-onset cases are probably more common than the medical literature suggests, because mild or episodic symptoms can be attributed to psychiatric illness, migraines, viral infections, or substance use. The delay between first symptoms and correct diagnosis can stretch for years.
Women, Pregnancy, and the Risk of Crisis
Calling female carriers “just carriers” understates the risk. Women with OTC mutations can and do develop hyperammonemic episodes, and pregnancy is a particularly vulnerable time. The metabolic demands of carrying a fetus, combined with the catabolic state after delivery, can tip a previously stable woman into crisis. One case study documented a woman with known OTC deficiency who delivered safely but then experienced a hyperammonemic crisis in the postpartum period, triggered by poor nutrition after discharge.6PubMed Central. Considerations for prenatal and postpartum management of a female patient with ornithine transcarbamylase deficiency Monthly monitoring and lab work throughout pregnancy and the weeks that follow can catch rising ammonia before it becomes dangerous.
Women who know they carry an OTC mutation should work with a metabolic specialist before becoming pregnant. Those who do not know they carry one may first learn about their condition when a postpartum crisis lands them in the ICU, which underscores the importance of family history screening when there is any suggestion of urea cycle problems in relatives.
Why It Gets Misdiagnosed as a Psychiatric Illness
When ammonia rises gradually rather than catastrophically, the symptoms can mimic psychiatric conditions: confusion, agitation, personality changes, hallucinations. One reported case involved a 37-year-old woman with borderline intellectual functioning who had a psychotic episode during an infection. She was initially diagnosed with schizophrenia and treated with antipsychotics. Only later, when a genetic workup was performed, did clinicians realize that her psychosis was driven by hyperammonemia from OTC deficiency.7PubMed Central. A late-onset Ornitin Transcabamylase deficiency case as an organic psychosis
This pattern is not unique to OTC deficiency; any urea cycle disorder can present with psychiatric-looking symptoms. The practical takeaway for patients and families is straightforward: if someone has unexplained episodes of confusion or behavioral change, especially ones that come and go or worsen after high-protein meals or illness, checking a blood ammonia level is a simple and inexpensive first step. It is not part of routine bloodwork, though, so it has to be specifically ordered.
The Challenge of Newborn Screening
You might assume that a condition this dangerous would be caught by the standard newborn heel-prick test. It usually is not. Current newborn screening programs rely on dried blood spot analysis, and OTC deficiency does not produce a single reliable marker in that format. Ammonia itself cannot be measured on a dried blood spot. Glutamine, which tends to rise when ammonia is high, is chemically unstable and degrades on the card, giving falsely low readings. Orotic acid, another potential clue, is elevated in the urine of OTC-deficient patients but is not a useful marker in blood.8International Journal of Neonatal Screening. Challenges in Newborn Screening for Urea Cycle Disorders This means many affected babies are only diagnosed after symptoms appear, and in the severe neonatal form, that can be dangerously late.
Some metabolic centers advocate for targeted screening in families with known OTC mutations, using genetic testing or enzyme assays on cord blood. But for the broader population, the technical hurdles remain unsolved, and OTC deficiency is not included in most countries’ universal screening panels.
Managing a Hyperammonemic Crisis
When ammonia surges acutely, the priority is bringing it down fast. Treatment in an emergency setting typically involves several tools used simultaneously: hemodialysis to physically remove ammonia from the blood, intravenous nitrogen scavenger drugs (sodium phenylacetate and sodium benzoate) that provide alternative pathways for nitrogen disposal, arginine supplementation to keep the remaining urea cycle running, and intravenous glucose and lipids to supply calories while protein is temporarily restricted.9Pediatrics. Late-Onset Ornithine Transcarbamylase Deficiency: Treatment and Outcome of Hyperammonemic Crisis Speed matters: the longer ammonia stays elevated, the greater the risk of permanent brain damage.
Not every hospital is equipped for this kind of management. Families often need to travel to specialized metabolic centers, and many carry emergency letters explaining the diagnosis so that local emergency rooms can start basic interventions without delay while arranging a transfer.
Day-to-Day Treatment
Between crises, chronic management centers on keeping ammonia from building up in the first place. This generally means three things working together: a protein-restricted diet, amino acid supplements, and nitrogen scavenger medications. Citrulline or arginine supplements help replenish intermediates the stalled urea cycle cannot make on its own, and ammonia scavenger drugs provide the body with backup routes for getting rid of nitrogen waste. In one study, the majority of patients with OTC or related urea cycle defects were managed on a combination of citrulline or arginine, scavenger drugs, and a low-protein diet, with dosing adjusted to severity.10PubMed Central. Citrulline in the management of patients with urea cycle disorders
Glycerol phenylbutyrate (GPB, sold under the brand name Ravicti) has become a commonly prescribed scavenger drug because it is a liquid taken by mouth, unlike older options that involved large volumes of unpleasant-tasting solutions. In young children transitioning to GPB, ammonia and glutamine levels remained well controlled, and the rate of hyperammonemic crises dropped from roughly three episodes per year to under one.11PubMed. Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years Data in infants under two months also showed stable drug metabolism and controlled ammonia levels during treatment.12PubMed Central. Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders
Even with effective medications, the daily reality is demanding. Protein-restricted diets require meticulous tracking and special medical foods. Parents describe struggling with anxiety about their child’s condition, difficulties getting medications into reluctant children, and challenges integrating their child into mainstream school. Some of this burden eased after switching to GPB, which is less unpleasant to take, but families reported that difficulties tied to the chronic nature of the illness persisted regardless of which medication was used.13PubMed Central. The burden of pharmacological treatment on health-related quality of life in people with a urea cycle disorder Practical issues like sourcing the right syringes for accurate dosing also added unexpected stress.
Liver Transplant as a Cure
Liver transplantation is currently the only way to fully correct OTC deficiency, because the liver is where nearly all urea cycle activity takes place. A healthy donor liver supplies the missing enzyme, and after transplant, patients can eat a normal diet and stop taking scavenger drugs. In a multicentre study of 20 OTC-deficient patients who received liver transplants, the overall survival rate was 95 percent. The single death occurred hours after surgery due to a vascular complication. About two-thirds of patients experienced at least one post-surgical complication such as rejection or bile leaks, but none had any further metabolic crises after transplant, and all discontinued their dietary restrictions and scavenger medications.14PubMed Central. Liver transplantation in ornithine transcarbamylase deficiency: A retrospective multicentre cohort study
Transplant is not a decision taken lightly. It carries surgical risk, requires lifelong immunosuppressive drugs to prevent organ rejection, and depends on donor organ availability. For patients with severe, recurrent crises or those whose disease is difficult to control with medication and diet, the trade-off often favors transplant. For patients with milder, well-controlled disease, the risks of transplant may outweigh the benefits, at least for now.
Gene Therapy on the Horizon
The limitations of transplant, chiefly the need for immunosuppression and the shortage of donor organs, have made OTC deficiency a focus for gene therapy research. Several strategies are under investigation, including adeno-associated viral (AAV) vectors that deliver a working copy of the OTC gene to liver cells, messenger RNA therapies that instruct liver cells to produce the enzyme temporarily, and genome-editing techniques that aim to correct the mutation directly.15PubMed Central. Genetic Therapy Approaches for Ornithine Transcarbamylase Deficiency
The history here carries a cautionary note. OTC deficiency was actually one of the first genetic diseases targeted by gene therapy in the late 1990s, and an early trial ended in the death of a young participant, Jesse Gelsinger, from a severe immune reaction to the adenoviral vector used at the time. That tragedy reshaped the entire field of gene therapy and led to stricter safety oversight. Modern AAV-based vectors are very different from the one used in that trial, and ongoing research has shown real promise. Still, no gene therapy for OTC deficiency has yet reached routine clinical use. Reviews of the field describe it as having “high unmet needs” while noting that effective gene therapy could eventually replace transplant by restoring enzyme activity without the need for lifelong immunosuppression or a donor organ.16PubMed Central. Gene therapy for urea cycle defects: An update from historical perspectives to future prospects
Triggers to Watch and Practical Precautions
For anyone living with OTC deficiency, whether a child on a protein-restricted diet or an adult with late-onset disease, knowing the common triggers for hyperammonemic episodes can be lifesaving. The biggest ones include:
- Illness or infection: Fever and inflammation increase protein breakdown in the body, flooding the urea cycle with more nitrogen than it can handle.
- High protein intake: Even a single unusually large protein meal can tip the balance in someone with marginal enzyme activity.
- Surgery or trauma: The stress response after an operation accelerates muscle protein breakdown.
- Fasting or starvation: When the body runs out of dietary fuel, it breaks down its own muscle for energy, releasing ammonia.
- Certain medications: Valproic acid (an anti-seizure and mood-stabilizing drug) is a well-known offender because it independently inhibits the urea cycle. Corticosteroids can also increase protein catabolism.
Families and patients typically carry “sick-day” protocols provided by their metabolic team: instructions on when to reduce protein intake further, when to increase calorie intake with low-protein foods, and when to head to the emergency room. Having an ammonia level drawn quickly is the single most important action during a suspected crisis, because treatment decisions hinge on that number.
When Adults Get Diagnosed for the First Time
Late-onset OTC deficiency in adults remains underappreciated. Some adults with partial enzyme function have survived for decades without a formal diagnosis, attributing their intermittent confusion, nausea, or headaches to migraines, stress, or food intolerance. A first hyperammonemic crisis in adulthood can be triggered by a new exercise regimen that increases protein supplementation, a crash diet, bariatric surgery, or a severe infection. Because emergency physicians rarely think of inborn metabolic disease in middle-aged patients, the diagnosis is frequently missed or delayed.
The psychiatric misdiagnosis pathway described earlier is one common detour, but there are others. Patients have been worked up for liver failure, drug overdose, or encephalitis before someone checks an ammonia level and finds it dramatically elevated. Awareness is slowly improving, but OTC deficiency remains a diagnosis that requires someone on the medical team to think of it. If you have a family history of unexplained infant deaths, siblings with intellectual disability, or relatives who avoid protein-rich foods without a clear reason, mentioning that history to a doctor could accelerate a diagnosis that might otherwise take years.
Dietary Reality and Special Medical Foods
Protein restriction sounds simple in principle but is remarkably complicated in practice, especially for growing children. Protein is in virtually everything, and the goal is not to eliminate it (the body still needs protein for growth and repair) but to limit it to the exact amount the impaired urea cycle can handle. This means carefully measured portions, specialized low-protein medical foods, and supplementation with essential amino acids to prevent nutritional deficiencies.
Many families rely on prescription low-protein flour, pasta, and bread substitutes. These products are not widely available in grocery stores and can be expensive, with insurance coverage varying by region. School lunches, birthday parties, and restaurant meals all become logistical puzzles. Dietitians specializing in metabolic disorders are essential members of the care team, but access varies widely, particularly outside major academic medical centers. For adults with late-onset disease, the adjustment can feel equally disorienting: learning to quantify every gram of protein in each meal while maintaining adequate calorie intake and avoiding the monotony that leads to poor adherence.